肺表面活性物质治疗新生儿肺透明膜病的疗效分析

    Pulmonary surfactant in treatment of hyaline membrane disease in neonate

    • 摘要: 目的: 探讨肺表面活性物质(pulmonary surfactant,PS)治疗新生儿肺透明膜病(hyaline membrane disease of newborn,HMD)的疗效。方法: 对17例HMD患儿气管内给予PS治疗,观察用药后的临床表现、呼吸机参数、血气分析结果、胸片的变化。结果: 用药后临床症状和体征改善。机械通气参数吸气峰压(PIP)、呼吸末正压(PEEP)、平均气道压(MAP)和呼吸频率(RR)较治疗前均降低(P<0.05~P<0.01);血气分析PaO2及pH值上升(P<0.05和P<0.01),PaCO2下降(P<0.01)。24 h胸片提示肺部病变明显改善。结论: PS治疗HMD可明显改善其转归,减少呼吸机上机时间、住院天数及病死率。

       

      Abstract: Objective: To explore the effect of pulmonary surfactant(PS) on hyaline membrane disease(HMD) of newborn.Methods: PS was administered to seventeen neonates with HMD,then the changes of clinical manifestation,the parameter of mechanical aeration,the results of blood gas and the X-ray presentations of the lung were observed.Results: After medical treatment,the symptoms and signs of the neonates were improved.The pressure peak of mechanical aeration parameter(PIP),positive breath pressure(PEEP),average gas trace pressure(MAP) and breath frequency(RR) dropped remarkably(P<0.05-P<0.01).The level of PaO2 and pH increased obviously(P<0.05 and P<0.01),and the level of PaCO2 decreased greatly(P<0.01).At 24 hours after treatment,the X-ray presentations improved significantly.Conclusions: PS therapy can improve the pathological changes of HMD,reduce the time of respirator utilization,the time of hospital stay and the fatality rate.

       

    /

    返回文章
    返回